Considerable effort has been made to override the T315I mutation ( Table 1). The ATP-noncompetitive Abl TKI, ON012380, was the first agent that was able to inhibit both wild-type and all imatinib ...

Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.